(ENOV) Enovis - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1940145022

Orthopedic Braces, Joint Implants, Surgical Tools, Compression Garments, Therapy

ENOV EPS (Earnings per Share)

EPS (Earnings per Share) of ENOV over the last years for every Quarter: "2020-03": 0.1, "2020-06": -0.19, "2020-09": 0.29, "2020-12": 0.72, "2021-03": 0.4, "2021-06": 0.56, "2021-09": 0.49, "2021-12": -0.03, "2022-03": 0.28, "2022-06": 2.21, "2022-09": -1.23, "2022-12": -1.01, "2023-03": -0.42, "2023-06": -0.18, "2023-09": -0.05, "2023-12": 0.05, "2024-03": -1.32, "2024-06": -0.34, "2024-09": -0.57, "2024-12": -12.59, "2025-03": -0.99,

ENOV Revenue

Revenue of ENOV over the last years for every Quarter: "2020-03": 816.356, "2020-06": 620.36, "2020-09": 805.931, "2020-12": 828.122, "2021-03": 879.211, "2021-06": 985.928, "2021-09": 965.891, "2021-12": 1023.273, "2022-03": 1023.368, "2022-06": 395.117, "2022-09": 383.814, "2022-12": 408.713, "2023-03": 406.151, "2023-06": 428.502, "2023-09": 417.524, "2023-12": 455.02, "2024-03": 516.266, "2024-06": 525.16, "2024-09": 505.222, "2024-12": 560.975, "2025-03": 558.834,

Description: ENOV Enovis

Enovis Corporation is a medical technology company that develops and markets clinically differentiated solutions globally, operating through two primary segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment offers a range of orthopedic solutions, including bracing, therapy products, and compression garments used by various healthcare professionals. The Reconstructive segment focuses on surgical implants for joint reconstruction and surgical productivity tools. Enovis distributes its products under the ESAB and DJO brands, both directly and through independent distributors.

From a business perspective, Enovis has a diversified product portfolio catering to different healthcare needs, from orthopedic care to reconstructive surgery. The companys products are used by a wide range of healthcare professionals, indicating a broad customer base. Its distribution strategy, combining direct sales with independent distributors, allows for a wide market reach.

Analyzing the provided , Enovis Corp (ENOV) is currently trading at $32.29, below its SMA20 and SMA50, indicating a short-term downtrend. The stock is also significantly below its SMA200, suggesting a longer-term downtrend. The ATR indicates a volatility of 4.30%, which is relatively moderate. The 52-week high and low are $49.33 and $29.65, respectively, showing that the stock has seen a significant price fluctuation over the past year.

From a fundamental standpoint, as per the , Enovis has a market capitalization of $1916.48M USD, with a forward P/E ratio of 10.72, suggesting the stock might be undervalued relative to its future earnings potential. However, the Return on Equity (RoE) is -27.45%, indicating that the company is currently not profitable in terms of equity returns.

Forecasting the stocks performance using both technical and fundamental data, the current downtrend and low RoE are concerning. However, the forward P/E ratio suggests potential for growth if the company can improve its earnings. A potential trading strategy could involve monitoring the stocks ability to break above its SMA20 and SMA50 levels, which could indicate a reversal in the short-term downtrend. Additionally, keeping an eye on the companys future earnings reports and guidance will be crucial, as an improvement in RoE and profitability could positively impact the stock price.

Given the current technical and fundamental landscape, a cautious approach is warranted. Investors should watch for signs of trend reversal and improvements in the companys financial health before making significant investment decisions.

Additional Sources for ENOV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ENOV Stock Overview

Market Cap in USD 1,843m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2008-05-08

ENOV Stock Ratings

Growth Rating -53.8
Fundamental -54.6
Dividend Rating 0.0
Rel. Strength -25.2
Analysts 4.55 of 5
Fair Price Momentum 25.90 USD
Fair Price DCF -

ENOV Dividends

Currently no dividends paid

ENOV Growth Ratios

Growth Correlation 3m -45.2%
Growth Correlation 12m -66.4%
Growth Correlation 5y -71.9%
CAGR 5y -8.26%
CAGR/Max DD 5y -0.12
Sharpe Ratio 12m -1.93
Alpha -44.93
Beta 0.941
Volatility 45.56%
Current Volume 968.9k
Average Volume 20d 1303.3k
What is the price of ENOV shares?
As of July 02, 2025, the stock is trading at USD 31.36 with a total of 968,869 shares traded.
Over the past week, the price has changed by +4.67%, over one month by +5.77%, over three months by -17.93% and over the past year by -29.29%.
Is Enovis a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Enovis (NYSE:ENOV) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -54.57 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ENOV is around 25.90 USD . This means that ENOV is currently overvalued and has a potential downside of -17.41%.
Is ENOV a buy, sell or hold?
Enovis has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy ENOV.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for ENOV share price target?
According to our own proprietary Forecast Model, ENOV Enovis will be worth about 28.7 in July 2026. The stock is currently trading at 31.36. This means that the stock has a potential downside of -8.61%.
Issuer Target Up/Down from current
Wallstreet Target Price 56.5 80.2%
Analysts Target Price 56.5 80.2%
ValueRay Target Price 28.7 -8.6%